Impact of the Adjunctive Use of Omega‐3 in Periodontitis Patients With Diabetes on Local and Systemic Chemerin Levels: A Randomized Clinical Trial
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Dentistry
- Vol. 2025 (1) , 7927250
Abstract
Aims: The present study aspired to evaluate the impact of the adjunctive use of omega‐3 with nonsurgical periodontal therapy on clinical parameters as well as local and systemic chemerin levels as a marker of cardiovascular disease risk in periodontitis patients with diabetes. Methods: This randomized clinical trial was performed on thirty periodontitis patients with type II diabetes divided into two equal groups, both treated by nonsurgical periodontal treatment with the adjunctive use of daily 1000 mg Omega‐3FAs in group I only for 6 months. Patients were reexamined after 2 weeks (baseline), 3, and 6 months for recording the clinical parameters as follows: plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). Chemerin levels were assessed in both serum and GCF samples, HbA1c levels were also assessed. Results: Omega‐3FAs‐treated group recorded a more statistically significant improvement in clinical parameters compared to the control group, particularly concerning PD and CAL. A statistically significant reduction of HbA1c levels between baseline, 3 and 6 m values was encountered in Omega‐3FAs treated group, while no significant difference was evident in the control group. Additionally, Omega‐3FAs treated group recorded a more statistically significant reduction of GCF and serum chemerin levels in comparison to the control group after 6 months of therapy. Conclusion: The adjunctive use of omega‐3FAs with nonsurgical periodontal therapy has resulted in significant improvement of clinical periodontal parameters and glycemic control in periodontitis patients with type II diabetes, alongside the additional benefit of reducing both local and systemic chemerin levels, a biomarker for cardiovascular risk. Trial Registration: Clinical Trial Registry identifier: NCT06463535Keywords
This publication has 40 references indexed in Scilit:
- Effectiveness of periodontal treatment to improve glycemic control: an umbrella reviewActa Diabetologica, 2022
- n-3 polyunsaturated fatty acids regulate chemerin in cultured adipocytes: role of GPR120 and derived lipid mediatorsFood & Function, 2020
- Omega‐3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trialJournal of Periodontology, 2020
- New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular DiseaseCurrent Atherosclerosis Reports, 2019
- Periodontitis is associated with systemic inflammation and vascular endothelial dysfunction in patients with lacunar infarctJournal of Periodontology, 2018
- Chemerin in human cardiovascular diseaseVascular Pharmacology, 2018
- High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events — Insights from phenotype and genotype characterizationVascular Pharmacology, 2016
- Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failureClinica Chimica Acta, 2015
- The Effect of Nonsurgical Periodontal Therapy on Hemoglobin A1cLevels in Persons With Type 2 Diabetes and Chronic PeriodontitisJAMA, 2013
- Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes StudyJournal of Clinical Periodontology, 2006